Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SD118: Amend Phase I

NDL submitted a protocol amendment to the U.K.'s MHRA

Read the full 93 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE